ArticlemBio2021
Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Engineering single-dose plasmid DNA for sustained in vivo delivery of designer incretins.Trends in biotechnology · 2026Article
- A versatile capsule-intravaginal ring platform enables rapid and sustained release of monoclonal antibodies for non-hormonal contraception.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Improvement in binding and function of a monoclonal antibody against Shigella flexneri 3a O-antigen via phage display and whole-cell in-solution panning.The Journal of biological chemistry · 2026Article
- Biologic drug development for treatment and prevention of sexually transmitted infections.Clinical microbiology reviews · 2025Review
- Terminal complement complexes with or without C9 potentiate antimicrobial activity againstmBio · 2025Article
- Rapid In Vivo Screening of Monoclonal Antibody Cocktails Using Hydrodynamic Delivery of DNA-Encoded Modified Antibodies.Biomedicines · 2025Article
- Fc-modification of anti-PcrV gene-encoded antibodies modulates complement-mediated killing of Pseudomonas aeruginosa.Frontiers in immunology · 2025Article
- Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance.International journal of molecular sciences · 2024Review
- Evaluating vaccine-elicited antibody activities againstInfection and immunity · 2023Article
- Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target.Microbiology and molecular biology reviews : MMBR · 2023Review
- Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy.Antibodies (Basel, Switzerland) · 2023Review
- Vertebrate and Invertebrate Animal and New In Vitro Models for StudyingPathogens (Basel, Switzerland) · 2023Review
- Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy.Frontiers in reproductive health · 2023Review
- Engineered DNA-encoded monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein confer single dose protection in a murine malaria challenge model.Scientific reports · 2022Article
- A new dawn for monoclonal antibodies against antimicrobial resistant bacteria.Frontiers in microbiology · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Elizabeth M ParzychVaccine & Immunotherapy Center, The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA.
Sunita GulatiDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Bo ZhengDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Mamadou A BahVaccine & Immunotherapy Center, The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA.
Sarah T C ElliottVaccine & Immunotherapy Center, The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA.
Jacqueline D ChuVaccine & Immunotherapy Center, The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA.
Nancy NowakDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
George W ReedDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Frank J BeurskensGenmab, Utrecht, The Netherlands.
Janine SchuurmanDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Peter A RiceDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
David B WeinerVaccine & Immunotherapy Center, The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, USA.
Sanjay RamDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA sanjay.ram@umassmed.edu.
University of Massachusetts Chan Medical School · USThe Wistar Institute · USGenmab (Netherlands) · NL
Funding
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoeaR01AI132296 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2017 to 2021
$5.5MNovel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infectionR01AI141236 · NIAID · WISTAR INSTITUTE · PI WEINER, DAVID B. · 2019 to 2022
$4.6MTraining in Emerging Infectious DiseasesT32AI055400 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHERRY, SARA, HENSLEY, SCOTT ERIC · 2003 to 2022
$4.4MA novel vaccine against multidrug-resistant gonorrheaR01AI141181 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2019 to 2023
$4.3MImmune defenses against Neisseria gonorrhoeaeR01AI114790 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2015 to 2019
$3.1MVaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia coU01AI118161 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY · 2014 to 2017
$2.0MLipooligosaccharide mimitope vaccines against Neisseria gonorrhoeaeR01AI114710 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GULATI, SUNITA, RICE, PETER A. · 2015 to 2018
$1.8MNIAID NIH HHS R01 AI114710NIAID NIH HHS R01 AI114790NIAID NIH HHS R01 AI132296NIAID NIH HHS R01 AI141181NIAID NIH HHS R01 AI141236NIAID NIH HHS T32 AI055400NIAID NIH HHS U01 AI118161
Abstract
Monoclonal antibody (MAb) 2C7 recognizes a lipooligosaccharide epitope expressed by most clinical
Indexed as
Immunization, PassiveAnimalsAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacterial VaccinesComplement ActivationEpitopesFemaleGonorrheaImmunoglobulin GMiceMice, Inbred BALB CNeisseria gonorrhoeaeAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacterial VaccinesEpitopesImmunoglobulin GcomplementDNA-delivered monoclonal antibodygonorrheamonoclonal antibodiesNeisseria gonorrhoeae
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.